Molecular Partners Ag (MOLN) Change in Account Payables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Account Payables of $192.83 for Q1 2026, down 75.09% year-on-year from $774.13 in Q1 2025, and down 99.76% on a QoQ basis from $80794.3 in Q4 2025.
Molecular Partners Ag (MOLN) Change in Account Payables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Account Payables for 7 consecutive years, with $192.83 the latest figure, recorded in Q1 2026.
- Quarterly Change in Account Payables fell 75.09% year-over-year to $192.83 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69236.3 (down 86.74% YoY) and the FY2025 annual result came in at $81326.0, down 86.4% from the prior year.
- Change in Account Payables retreated to $192.83 in Q1 2026 per MOLN's latest filing, from $80794.3 in the prior quarter.
- Over the last five years, Change in Account Payables for MOLN reached as high as $1.9 million in Q3 2022 and fell as low as -$5.5 million in Q4 2022.
- A 5-year average of -$345940.2 and a median of $773.03 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 407.97% — and 2024, when it soared 174.63%.
- Year by year, Change in Account Payables stood at -$5.5 million in 2022, then soared by 83.47% to -$915352.1 in 2023, then surged by 165.22% to $596955.4 in 2024, then sank by 86.47% to $80794.3 in 2025, then slumped by 99.76% to $192.83 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $192.83, $80794.3, and -$338248.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 192.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.83 |
| Mar 31, 2026 | 192.83 |
| Dec 31, 2025 | 80,794.29 |
| Dec 31, 2025 | 80,794.29 |
| Sep 30, 2025 | -338,248.38 |
| Sep 30, 2025 | -338,248.38 |
| Jun 30, 2025 | 326,497.56 |
| Jun 30, 2025 | 326,497.56 |
| Mar 31, 2025 | 774.13 |
| Mar 31, 2025 | 774.13 |
| Dec 31, 2024 | 596,955.43 |
| Dec 31, 2024 | 596,955.43 |
| Sep 30, 2024 | -1.78 Mn |
| Sep 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2,122.95 |
| Mar 31, 2024 | 2,122.95 |
| Dec 31, 2023 | -915,352.08 |
| Dec 31, 2023 | -915,352.08 |